Kidney function may alter how a cancer drug works — a trial investigates
NCT ID NCT07734610
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study examines how the body processes nemtabrutinib in people with severe kidney impairment compared to healthy volunteers. By measuring drug levels in the blood after a single dose, researchers aim to understand whether kidney function changes how the drug is handled. The results could guide future dosing recommendations for patients with kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemtabrutinib
- What this could lead to
- If successful, this could help determine the right dose of nemtabrutinib for people with severe kidney disease.
- What could go wrong
- This is a small, early-stage study focused on drug processing, not on treating a disease. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test